Oxybenzamide derivatives useful for inhibiting factor Xa or viia

US6953857B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Marc Nazare · Idstein, DE
• David William Will · Schwalbach, DE
• Anuschirwan Peyman · Kelkheim, DE
• Hans Matter · Langenselbold, DE
• Gerhard Zoller · Blankenloch, DE
• Uwe Gerlach · Hattersheim, DE

Key dates

• Filing date: Dec 21, 2001
• Grant date: Oct 11, 2005
• Expiry date: Jul 19, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds comprising the following formula:R0—Q—X—Q′—W—U—V—G—M  (I)These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.